Literature DB >> 19633843

A different role for FDG PET/CT in axillary lymph node staging in breast cancer.

Tjeerd S Aukema, Marieke E Straver, Renato A Valdés Olmos, Wouter V Vogel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19633843     DOI： 10.1007/s00259-009-1211-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  5 in total

1.  Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer.

Authors:  A Gil-Rendo; G Zornoza; M J García-Velloso; F M Regueira; C Beorlegui; M Cervera
Journal:  Br J Surg       Date:  2006-06       Impact factor: 6.939

2.  Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer.

Authors:  Jacobus J M van der Hoeven; Otto S Hoekstra; Emile F I Comans; Rik Pijpers; Robert P A Boom; Dick van Geldere; Sybren Meijer; Adriaan A Lammertsma; Gerrit J J Teule
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

3.  A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.

Authors:  U Veronesi; C De Cicco; V E Galimberti; J R Fernandez; N Rotmensz; G Viale; G Spano; A Luini; M Intra; P Veronesi; A Berrettini; G Paganelli
Journal:  Ann Oncol       Date:  2006-12-12       Impact factor: 32.976

4.  Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.

Authors:  David Fuster; Joan Duch; Pilar Paredes; Martín Velasco; Montserrat Muñoz; Gorane Santamaría; Montserrat Fontanillas; Francesca Pons
Journal:  J Clin Oncol       Date:  2008-08-11       Impact factor: 44.544

5.  Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients.

Authors:  Till A Heusner; Sherko Kuemmel; Steffen Hahn; Angela Koeninger; Friedrich Otterbach; Monia E Hamami; Klaus R Kimmig; Michael Forsting; Andreas Bockisch; Gerald Antoch; Alexander Stahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-05       Impact factor: 9.236
  5 in total
  5 in total

Review 1.  Metabolic positron emission tomography imaging in cancer detection and therapy response.

Authors:  Aizhi Zhu; Daniel Lee; Hyunsuk Shim
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

2.  Staging the axilla in breast cancer patients with ¹⁸F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems?

Authors:  Dimitri Bellevre; Cécile Blanc Fournier; Odile Switsers; Audrey Emmanuelle Dugué; Christelle Levy; Djelila Allouache; Cédric Desmonts; Hubert Crouet; Jean-Marc Guilloit; Jean-Michel Grellard; Nicolas Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

3.  Pretreatment PET in breast cancer: is there a role?

Authors:  Sue Chua; Ashley M Groves
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12       Impact factor: 9.236

4.  PET Probe-Guided Surgery in Patients with Breast Cancer: Proposal for a Methodological Approach.

Authors:  Paolo Orsaria; Agostino Chiaravalloti; Alessandro Fiorentini; Chiara Pistolese; Gianluca Vanni; Alessandra Vittoria Granai; Dimitrios Varvaras; Roberta Danieli; Orazio Schillaci; Giuseppe Petrella; Oreste Claudio Buonomo
Journal:  In Vivo       Date:  2017-01-02       Impact factor: 2.155

5.  Imaging lymphatic system in breast cancer patients with magnetic resonance lymphangiography.

Authors:  Qing Lu; Jia Hua; Mohammad M Kassir; Zachary Delproposto; Yongming Dai; Jingyi Sun; Mark Haacke; Jiani Hu
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.